Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Ramucirumab + Chemo in Advanced Gastric Cancer with Liver Metastasis
NCT06564298Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and ramucirumab in gastric cancer (GC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective Response Rate at 12 months. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
sintilimabramucirumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06564298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06564298.